Immune-related adverse events and the balancing act of immunotherapy

被引：0
作者：
Michael Conroy
Jarushka Naidoo
机构：
[1] Beaumont RCSI Cancer Centre,
[2] Beaumont Hospital,undefined
[3] RCSI University of Health Sciences,undefined
[4] Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins University,undefined
来源：
Nature Communications | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
引用
收藏
相关论文
共 23 条
[1]  
Hodi FS(2018)Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Lancet Oncol. 19 1480-1492
[2]  
Maher VE(2019)Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody J. Clin. Oncol. 37 2730-2737
[3]  
Eggermont AMM(2020)Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial JAMA Oncol. 6 519-527
[4]  
Shankar B(2020)Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer JAMA Oncol. 6 1952-1956
[5]  
Suresh K(2020)Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer Clin. Lung Cancer 21 e169-e170
[6]  
Naidoo J(2020)Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors J. Clin. Oncol. 38 105-106
[7]  
Dall’Olio FG(2017)Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy J. Clin. Oncol. 35 709-717
[8]  
Di Nunno V(2017)Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma J. Clin. Oncol. 35 785-792
[9]  
Massari F(2018)Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer J. Clin. Oncol. 36 2872-2878
[10]  
Naidoo J(2021)Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study Ann. Intern. Med. 174 641-648
123